Every intervention Outliyr has scored for focus and mental clarity, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for focus and mental clarity; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
85 of 138 evaluated interventions score 3.0+ out of 10 for focus and mental clarity · 21 comparisons
Attention remains one of neurofeedback's best-known use cases, but the claim needs caveats. Arns 2009 reported favorable ADHD symptom effects, while Cortese 2016 and Westwood 2025 found weaker or null effects on…
Caffeine-stack synergy is the main evidence base: Owen 2008, Giesbrecht 2010, Kelly 2008, and Haskell 2008 support attention and reaction-time benefits. Mátyus 2025 tempers standalone cognition claims. That makes L-Theanine more defensible…
Mori 2009 anchors the most relevant signal. Lion's Mane fits cognition focus when the goal is gentle mushroom-based support for cognition, mood, nerve biology, or gut-immune signaling over weeks. The score stays…
Ramsay 2007 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: Acute focus claims are supported mainly by small neuroimaging data and community experience. this verified source…
Dolan 2019 reports Brain creatine and cognitive processing review. Avgerinos 2018 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Creatine Monohydrate matters for this use…
De Baaij 2015 anchors the most relevant signal. Magnesium fits cognition focus when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible. The score stays bounded because…
Several small trials show improved attentional performance and inhibitory control with RF training, though Rosendo da Cunha e Silva 2026 systematic review notes HRV gains do not consistently translate to working-memory gains.…
Sacks 2001 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: this verified source found mild dehydration worsened mood, concentration, headache, and perceived task difficulty in women.…
Lang 2024 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: Aerobic exercise is one of the best-supported non-drug cognitive interventions, especially in aging and sedentary populations.…
Tzang 2024 reports 25 RCTs and 1024 participants; lower SBP, DBP, fasting blood glucose, and triglycerides; no significant adverse-effect excess. Tzang 2024 points in the same direction, but route, dose, baseline status,…
Naeser 2011 reported cognitive improvements after transcranial red and near-infrared LED treatments in chronic mild TBI. That is promising, but it is not broad proof for healthy focus enhancement. The best-fit user…
Friling et al. 2025 supports the core mechanism. FDA qualified claim status and older AAMI trials support targeted cognition use in elderly adults. Crook 1991 and Cenacchi 1993 are the main positive…
The best human cognitive signal is Russian attention and operative-memory work, including Asmarin et al. 1997 and Kaplan et al. 1996, plus strong animal learning data from Dolotov et al. 2006. That…
The cognition signal comes mainly from Baker 2012, which reported improved cognitive function in older adults after GHRH analog treatment. A 2025 HIV neurocognition trial was smaller and did not show a…
The evidence points to a plausible use case without proving a universal response. Muller U et al. 2013 is the best anchor here because it reports healthy-volunteer study supporting a mixed cognitive…
Older-adult cognition trials and chronic neurorehab studies justify a meaningful score. Hadanny 2020 reports gains in attention, processing speed, and executive function after sixty hard-chamber sessions. The effect is protocol-heavy and not…
The existing rationale points to this narrower claim: Cognition support comes mostly from sauna-bathing cohort data and acute post-session mental clarity. this verified source found frequent sauna bathing predicted lower. That does…
Harrison 2009 anchors the most relevant signal. Rapamycin fits cognition focus when mTORC1 modulation, autophagy, immune aging, or senescence biology is the actual target. The score stays bounded because human longevity endpoints…
The human or mechanistic literature points most directly at attention, focus, or cognitive-task performance. The strongest support comes from Yoo C. et al. 2021, but the practical rating stays bounded by study…
Nishimaki 2018 reports MCI RCT; cognitive signal appeared strongest in APOE4 carriers. The score stays conditional because Molecular Hydrogen still needs better outcome data for this exact use case. The practical move…
Long-term flavonoid intake associates with less subjective cognitive decline in large cohorts, and cocoa flavanols acutely improve cerebral blood flow and have shown small working-memory and processing benefits in some trials. But…
Kong 2024 found no significant overall cognitive improvement in epilepsy patients despite seizure, mood, and quality-of-life improvements. The score stays bounded because Vagus Nerve Stimulation evidence for cognition focus can depend on…
Cognition support is biologically plausible but lacks a dedicated cognitive-battery RCT. The Voznesenskaia 2010 multicenter trial captured concentration and attention improvement inside the asthenia outcome rather than as a primary endpoint. The…
The evidence points to a plausible use case without proving a universal response. Chen X et al. 2026 is the best anchor here because it reports 41 randomized trials, 2,287 participants and…
The existing rationale points to this narrower claim: this verified source supports hippocampal LTP rescue in APP/PS1 mice, especially females. No human cognition trial exists. That does not make Ca-AKG (Calcium Alpha-Ketoglutarate)…
Liu 2024 reports 11 RCTs; 346 healthy participants; significant improvements reported across fatigue, cognition, and exercise-efficiency endpoints overall; endpoint details are limited. The score stays conditional because Astaxanthin still needs better outcome…
The evidence points to a plausible use case without proving a universal response. D'Onofrio et al. 2021 is the best anchor here because it reports review of preclinical and small clinical Alzheimer's…
Zajac 2025, the largest human trial at 147 older adults with subjective memory complaints, found dose-dependent gains in subjective prospective memory and sleep initiation at 25 mg/day over 16 weeks, but an…
The evidence points to a plausible use case without proving a universal response. Leung GKW et al. 2025 is the best anchor here because it reports 33 randomized trials and 2821 individuals…
The human or mechanistic literature points most directly at attention, focus, or cognitive-task performance. The strongest support comes from Dinda B. et al. 2015, but the practical rating stays bounded by study…
Xu et al. 2018 supports a plausible benefit. Gonzales 2023 was a 5-person Alzheimer's feasibility trial of D+Q; it supports CNS-penetrance questions, not cognitive efficacy. The score stays bounded because Senolytics evidence…
Cognition is the only use case where noopept carries a human endpoint rather than a mechanism. Both identifiable trials measured MMSE in people with vascular or post-traumatic cognitive impairment and reported gains…
That study reported modest improvements in cognitive tests and cerebrovascular function, but the sample was limited to older women and the intervention lasted two years. No comparable trials have reproduced these findings…
Tirzepatide and the cognition-focus label rely on observational reports and preclinical studies that hint at possible brain benefits, but the data remain indirect. The current evidence tier is low because randomized controlled…
The human or mechanistic literature points most directly at attention, focus, or cognitive-task performance. The strongest support comes from Malykh A. et al. 2010, but the practical rating stays bounded by study…
Norwegian 4x4 aims to boost aerobic capacity, which can raise cerebral blood flow and stimulate brain-derived neurotrophic factor, a protein linked to learning and memory. The evidence linking HIIT to acute alertness…
Soh 2024 anchors the most relevant signal. Glycine fits cognition focus because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the endpoint. The score stays bounded because…
The strong dementia and Alzheimer association from Laukkanen 2017 is a long-term, disease-prevention protective signal driven largely by better cardiovascular and vascular health, not an acute focus or productivity effect. Many users…
Cranial application has mixed evidence and wellness cognition claims remain unproven. PEMF is not a reliable nootropic. The most defensible cognitive angle is indirect improvement from pain reduction or better sleep in…
Observational diabetes cohorts suggest possible dementia-risk reduction, but causality remains uncertain Bannister 2014. Metformin's cognition case is strongest when improved glucose control reduces vascular stress, not when healthy users expect a nootropic…
The evidence points to a plausible use case without proving a universal response. Zhu et al. 2026 is the best anchor here because it reports 20 studies, 1249 participants and improved memory,…
Kumar 2021 reported improved cognitive test scores and verbal fluency in older adults over 24 weeks, declining after stopping. This is a real but small open-label finding without a placebo arm, so…
The human or mechanistic literature points most directly at attention, focus, or cognitive-task performance. The strongest support comes from Cohen P. et al. 2020, but the practical rating stays bounded by study…
The human or mechanistic literature points most directly at attention, focus, or cognitive-task performance. The strongest support comes from Isaacson et al. 1991, but the practical rating stays bounded by study size,…
The human or mechanistic literature points most directly at attention, focus, or cognitive-task performance. The strongest support comes from Copani A. et al. 1992, but the practical rating stays bounded by study…
Semaglutide has interesting brain biology but no decisive human focus trial in this report. Yao 2024 supports metabolic improvements that can indirectly help cognition in diabetes or obesity. That is different from…
The human or mechanistic literature points most directly at attention, focus, or cognitive-task performance. The strongest support comes from Cintineo H. et al. 2022, but the practical rating stays bounded by study…
Adrenergic-driven alertness and reaction time benefit at acute doses; Sidney and Lefcoe 1977 found no benefit on reaction time, hand-eye coordination, or cognitive measures from a single 24 mg dose in 21…
McCoy 2013 anchors the most relevant signal. Dihexa fits cognition focus only as a research-chemical hypothesis around synaptogenesis and memory circuits, not as a proven human nootropic. The score stays bounded because…
Direct cognitive endpoints are J-147's strongest repeated finding across models. It corrected water-maze and recognition-memory deficits and improved cognition even in normal rodents (Chen et al. 2011). All of it is preclinical,…
Mechanistic interest via glutathione and glutamate modulation, but no strong direct cognition RCT base in healthy adults. Neuroprotective framing is mostly preclinical.
Schwarz 2022 SmartAge found no significant primary memory benefit after 12 months, though exploratory signals kept cognition from scoring lower.
The antioxidant and mitochondrial rationale is plausible for neurodegeneration, but large trials in Parkinson and Huntington disease were largely negative, and there is no convincing human evidence that CoQ10 improves focus or…
No direct cognitive RCTs outside neurological rehab context. Any cognitive benefit would be secondary to movement, mood, or Parkinson's motor support.
Selank looks more cognition-preserving than cognition-transforming. Human comparator studies describe mild nootropic or antiasthenic effects, while preclinical work such as Semenova 2007 supports learning under brain-stress models.
Cognition evidence is mixed. The audit could not verify the claimed VITAL omega-3 cognition source, so cognition scoring leans on narrower memory data such as Yurko-Mauro 2010 rather than broad prevention claims.
Higher aerobic fitness supports cerebral blood flow and BDNF, but the cognition evidence for sprint training specifically is indirect and derived mainly from broader fitness studies.
The cognitive case is widely overstated. Acute effects in healthy adults are small and mostly appear under fatigue: Evans 2018 found a ketone ester attenuated executive-function decline only after exhausting exercise. The…
Preserved v0.x score. No verified healthy-cognition ozone RCT was available in the audit, while neurological harm signals are concrete for gas routes. Khosravi 2024 reported cerebral gas embolism and multifocal ischemic stroke…
Cognition is the most-claimed and best-studied use, but the human signal is real and contested at once, so it scores moderate rather than high. In mild-to-moderate Alzheimer's, pooled trials showed a cognitive…
No direct cognition or focus benefit was verified. Tryptophan and tyrosine share large neutral amino acid transport with other EAAs, so neurotransmitter claims should stay modest.
Observational data link 25(OH)D status to cognitive function, but D3 supplementation RCTs are largely null on cognitive endpoints in healthy or mild cognitive impairment populations. The DO-HEALTH trial (Bischoff-Ferrari et al. 2020…
Deficiency can impair mood and mental clarity, and these improve with repletion, but there is little evidence that supplementing beyond adequacy sharpens focus or cognition in healthy adults. Vitamin C is not…
Cognition remains a 4 because evidence is preclinical or indirect. Tucker 2024 reported attenuation of Alzheimer's-like features in mice, and Pickart 2012 discusses cognitive-health mechanisms, but human focus data is absent.
Neuroprotective effects may support cognitive function indirectly in injury models. There is no direct healthy-adult focus trial, so cognition claims should remain conservative.
Indirect. Aerobic fitness associates with better cognition over time, but no rucking-specific cognitive data exists; this rides the general aerobic-exercise literature.
Cognition has no human trial of Tβ4. The rat TBI cognitive improvements, per Xiong 2011, are TBI-recovery findings, not healthy-cognition data.
Mood and arousal changes may improve perceived focus in some stressed users. No direct cognitive RCTs, attention endpoints, or memory endpoints justify stronger claims.
One 18-month RCT using Theracurmin (Small and colleagues 2018, n=40) showed memory and attention benefits, but a 2025 dose-response meta-analysis found effects only emerge around 0.8 g per day over at least…
At low doses kava does not appear to impair acuity, but it is not a cognitive enhancer. Higher doses sedate. No focus or cognition trials support a positive score.
No direct cognitive evidence supports BFR as a focus intervention.
No meaningful human cognition trials for spirulina; any benefit would be indirect via metabolic and vascular health.
Carrasco-Gallardo 2012 summarizes tau-aggregation and neuroprotection mechanisms, but shilajit-alone human cognition RCTs are absent.
Resistance training can improve executive function through exercise-mediated pathways, but EMS-specific cognitive trials are lacking. Any focus benefit is likely indirect through improved training adherence, mood, and metabolic health.
No human cognition-focus trial exists. Any cognitive rationale depends on immune-brain signaling and illness recovery, not direct nootropic evidence.
Animal and mechanistic models suggest BBB penetration and possible neuroprotective signaling, but there are no strong human cognition RCTs. Any subjective focus effect is more likely from better glucose control in dysregulated…
Cognitive evidence remains preclinical or indirect. Rajman 2018 summarizes NAD-booster biology, but no completed human NMN cognitive RCT establishes benefit.
No cognition or focus RCT supports glutathione supplementation; the Parkinson trials targeted motor symptoms and were null on controlled endpoints.
Wu 2025 found NAD+ rose 2.6- to 3.1-fold in long-COVID, but cognition, fatigue, sleep, anxiety, and depression did not significantly improve versus placebo.
The brain is mitochondria-dependent, but no verified human cognition RCT for SS-31 supports a higher score. This remains a mechanism-derived, not clinically proven, use case.
Memory improved in the D-galactose mouse model, but no human cognition trial supports a focus or memory claim.
TRT is weak for cognition. The T Trials cognition substudy found no meaningful improvement in memory or executive function in older men with low testosterone and age-associated memory impairment.
Yankouskaya 2023 Biology fMRI study (n=33) showed 5 min head-out 20 degC immersion altered coupling between default-mode, frontoparietal, and salience networks, with self-reported gains in alertness and attentiveness. Acute focus lift is…
Anti-neuroinflammatory effects could matter in selected inflammatory states, but Alzheimer prevention work was inconclusive or halted. Celecoxib is not a cognitive enhancer.
No randomized trial has tested C15:0 supplementation for memory, attention, executive function, dementia prevention, or mood. Ciesielski 2024 (Ciesielski 2024) discusses emerging biology but does not establish a cognitive indication. The v0…
Nothing matches those filters.
Monthly out-of-pocket cost at the most accessible legitimate channel, at the dose the score was given for. 29 of 85 are not priced yet; those cells are left blank rather than guessed.
| Intervention | Monthly cost | At dose | How you get it |
|---|---|---|---|
| Neurofeedback | Not priced yet | ||
| L-Theanine | $3–$8 | 200 mg L-theanine + 100 mg caffeine | Over the counter |
| Lion’s Mane | $20–$40 | 3 g/day fruiting body extract | Over the counter |
| Methylene Blue | $13–$40 | 0.5-5 mg oral | Over the counter |
| Creatine Monohydrate | Not priced yet | ||
| Magnesium | $10–$20 | 200-400 mg glycinate elemental | Over the counter |
| HRV Biofeedback | $5 | 20 min/session at individual RF (4.5 to 6.5 bpm) | Over the counter |
| Electrolytes | Not priced yet | ||
| Zone 2 Cardio | Not priced yet | Over the counter | |
| Taurine | $3–$10 | 1-3 g, 30-60 minutes before sleep | Over the counter |
| Red Light Therapy | $17–$43 | 10-20 min at 6-12 inches, full chest/face/back rotation | Over the counter |
| Phosphatidylserine | $20–$50 | 300 mg/day total, split as 100 mg three times daily or 300 mg once daily with food | Over the counter |
| Semax | $12–$60 | 300-600 mcg/day of 0.1% spray | Grey market |
| Tesamorelin | $250–$500 | 2 mg subcutaneous daily in the evening | Prescription |
| Modafinil | $18–$35 | 200 mg oral tablet | Prescription |
| Hyperbaric Oxygen Therapy | $3,000–$6,000 | 2.0 ATA for 90 minutes with air breaks | In clinic |
| Infrared Sauna | $36–$73 | 55-60 degrees C, 20-30 min | Over the counter |
| Rapamycin | $15–$50 | 3 mg | Prescription |
| Paraxanthine (Enfinity) | Not priced yet | ||
| Molecular Hydrogen | Not priced yet | ||
| Polyphenols (Dietary) | Not priced yet | ||
| Vagus Nerve Stimulation | $4–$8 | 10-20 min auricular tVNS at comfortable perceptible intensity | Over the counter |
| Bromantane (Ladasten) | $12–$30 | 30 mg | Grey market |
| Time-Restricted Eating | Not priced yet | ||
| Ca-AKG (Calcium Alpha-Ketoglutarate) | $15–$30 | 1 g/day generic Ca-AKG oral | Over the counter |
| Astaxanthin | Not priced yet | ||
| Saffron | Not priced yet | ||
| Ergothioneine | Not priced yet | ||
| Ketogenic Diet | $100 | Standard keto, 40-50 g total carbohydrate/day | Over the counter |
| Sabroxy (Oroxylum indicum Extract) | Not priced yet | ||
| Senolytics | Not priced yet | ||
| Noopept (Omberacetam) | $5–$27 | 20 mg | Grey market |
| Resveratrol | Not priced yet | ||
| Tirzepatide | $299–$449 | 2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg | Prescription |
| Phenylpiracetam (Phenotropil) | $21–$42 | 100-200 mg | Grey market |
| Norwegian 4×4 | Not priced yet | Over the counter | |
| Glycine | $2–$3 | 3 g oral glycine | Over the counter |
| Traditional Sauna (Finnish Dry-Heat) | $50 | 15 to 20 minutes at 80 to 100 C | Over the counter |
| PEMF (Pulsed Electromagnetic Field Therapy) | $3–$117 | 20-30 min mat session | Over the counter |
| Metformin | $4–$30 | 500 mg with dinner for 1 week, then 500 mg twice daily for 1 week, then increase by 500 mg/week toward 1000 mg twice daily as tolerated | Prescription |
| Ashwagandha | $15–$30 | 300 mg KSM-66 with breakfast and 300 mg with dinner | Over the counter |
| GlyNAC (Glycine + N-Acetylcysteine) | $10–$30 | Glycine and NAC at ~100 mg/kg/day each | Over the counter |
| Piracetam (Nootropil) | $8–$20 | 2.4-4.8 g | Grey market |
| Aniracetam | $10–$25 | 750-1,500 mg | Grey market |
| Oxiracetam | $15–$40 | 800-2,400 mg | Grey market |
| Semaglutide | $199–$349 | 0.25 mg weeks 1 to 4, 0.5 mg weeks 5 to 8, 1.0 mg weeks 9 to 12, 1.7 mg weeks 13 to 16, 2.4 mg week 17 onward | Prescription |
| Dynamine (Methylliberine) | Not priced yet | ||
| Ephedrine | Not priced yet | ||
| Dihexa | $30–$60 | 8-12 mg/day sublingual | Research use only |
| J-147 | Not priced yet | ||
| NAC (N-Acetylcysteine) | $5–$15 | 600 to 1,200 mg/day | Over the counter |
| Spermidine | $40–$90 | 1-3 mg/day oral WGE | Over the counter |
| Coenzyme Q10 (CoQ10 / Ubiquinol) | $15–$40 | 100-200 mg/day | Over the counter |
| Whole-Body Vibration | $50–$100 | 30 Hz, roughly 0.3g, 10-20 min standing | Over the counter |
| Selank | $30–$60 | 0.15% intranasal spray, roughly 1-3 sprays per nostril per day depending on actuation size | Grey market |
| Omega-3 | $20–$40 | 1-2 g/day combined EPA+DHA | Over the counter |
| Sprinting (Sprint Interval Training) | Not priced yet | ||
| Exogenous Ketones | $38–$300 | Ester 10 to 25 g BHB | Over the counter |
| Ozone Therapy | $520–$2,600 | 20-30 mcg/mL ozone, roughly 1,000-1,500 mcg total per session | In clinic |
| Cerebrolysin | $500–$900 | About 30 mL per day IV | Grey market |
| Essential Amino Acids | Not priced yet | ||
| Vitamin D3 + K2 | Not priced yet | ||
| Vitamin C (Ascorbic Acid) | Not priced yet | ||
| GHK-Cu | $30–$100 | 0.5-3% topical serum or cream | Over the counter |
| BPC-157 | $40–$80 | 250 to 500 mcg SC 1 to 2x/day near injury site | Grey market |
| Rucking (Weighted Walking) | Not priced yet | ||
| Thymosin Beta-4 (Tβ4) | Not priced yet | ||
| Tongkat Ali | $20–$40 | 200 mg/day Physta standardized extract | Over the counter |
| Curcumin | $15–$40 | 500 mg curcuminoids | Over the counter |
| Kava (Piper methysticum) | Not priced yet | ||
| Blood-Flow Restriction Training | Not priced yet | ||
| Spirulina | $10–$25 | 1 to 4.5 g/day | Over the counter |
| Shilajit | $25–$50 | 500 mg purified shilajit | Over the counter |
| Full-Body EMS | Not priced yet | ||
| Thymosin Alpha-1 | $100–$400 | 1.6 mg subcutaneous | Prescription |
| Berberine | $15–$25 | 500 mg berberine HCl three times daily with meals | Over the counter |
| NMN (Nicotinamide Mononucleotide) | $40–$100 | 500 mg/day oral | Over the counter |
| Glutathione (GSH) | $20–$45 | 1,000 mg/day | Over the counter |
| NR (Nicotinamide Riboside) | $40–$50 | 250-300 mg/day oral | Over the counter |
| SS-31 (Elamipretide) | $200–$500 | 5-10 mg/day subcutaneous | Grey market |
| Pine Pollen | $20–$45 | 5 to 10 g powder per day | Over the counter |
| TRT (Testosterone Replacement Therapy) | $50–$300 | Clinician-selected formulation at the lowest dose likely to restore physiologic testosterone | Prescription |
| Cold Plunge | Not priced yet | Over the counter | |
| Celebrex (Celecoxib) | Not priced yet | ||
| C15 (Pentadecanoic Acid) | $40–$50 | 200 mg/day | Over the counter |
Head-to-head reports and category rankings that name a winner on this use case.
Ranked by the live Focus and cognition subrating, not the overall score. Methylene blue leads at 6.5–7.0/10 despite a lower overall, 6.0–6.5/10. Bromantane climbs from ninth to fourth.…
Semax scores 7.1/10 against noopept's 6.2/10 and wins five of the eight use cases both reports score. Noopept is oral, cheaper at $5 to $27 a month, and…
Melatonin, dosed low. It scores 7.5–8.0/10 against apigenin's 5.5–6.0/10 and wins the sleep rows outright. The morning hangover apigenin markets against comes from taking too much, not from…
Both score anxiety 7.5–8.0/10, so the tie-breaker is time. L-theanine works in about an hour and you take it when you need it. Ashwagandha takes eight weeks and…
Bromantane, for anything you plan to repeat. It scores 7.0–7.5/10 against phenylpiracetam's 5.5–6.0/10 and wins every shared use case that is not a floor tie: energy 6.2/10 to…
Cerebrolysin scores 6.0–6.5/10 and P-21 scores 5.0–5.5/10, and the gap is entirely about human data. Cerebrolysin has thousands of trial participants, contested by two independent Cochrane reviews. P-21…
CoQ10 scores 7.0–7.5/10 and methylene blue 6.0–6.5/10, yet methylene blue wins eleven of the seventeen shared use cases. The overall gap is risk, not effect. Methylene blue inhibits…
Neither, yet. Both have zero human trials, zero human pharmacokinetics and research-only access. PE-22-28 scores 4.5–5.0/10 and dihexa 4.0–4.5/10, and the gap is entirely safety: dihexa potentiates the…
Epitalon, if sleep is the question. It scores sleep quality 6.5–7.0/10 against pinealon's 1.5–2.0/10, because it acts on the pineal gland and melatonin output while pinealon is a…
No, and the reason is mechanical. A drink raises blood ketones in an hour. It does not lower insulin, deplete glycogen or shift fuel use. The diet scores…
Buy the panel. Red light therapy scores 7.5–8.0/10 against HBOT's 5.5–6.0/10, costs $17 to $43 a month against $3,000 to $6,000, and does not lose a single use…
Lion's Mane scores 7.0–7.5/10 and the reishi, cordyceps and chaga blend category scores 5.0–5.5/10. If cognition is the goal, buy the one species: lion's mane takes cognition-focus 7.0/10…
Neurofeedback, at 8.0–8.5 out of 10 for focus and mental clarity. Attention remains one of neurofeedback's best-known use cases, but the claim needs caveats.
Of the top-scoring options, L-Theanine is the least expensive at about $3 a month, scoring 7.5–8.0 out of 10 for focus and mental clarity.
Dihexa scores 5.0–5.5 out of 10 for focus and mental clarity but only 4.0–4.5 overall, landing in the caution tier once safety, side effects, cost and effort are counted.
85 of the 138 interventions evaluated for focus and mental clarity score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
